Form 4: Novavax Executive Elaine O'Hara Reports Stock Transactions
SEC Form 4 Filing
EVP and Chief Strategy Officer of Novavax, Elaine O'Hara, reports the vesting and subsequent disposal of shares to cover tax obligations.
Summary
- On March 1, 2024, Elaine O'Hara, EVP and Chief Strategy Officer of Novavax, reported transactions involving Novavax common stock.
- 19,600 restricted stock units vested and were converted into common stock.
- 5,375 shares were disposed of to satisfy tax withholding obligations at a price of $5.39 per share.
- Following these transactions, O'Hara directly owns 14,225 shares of Novavax common stock and 39,200 restricted stock units.
Sentiment
Score: 5
Explanation: The document is a routine regulatory filing detailing stock transactions by a company executive. It doesn't inherently convey positive or negative sentiment.
Industry Context
Form 4 filings are standard practice for company insiders to report transactions in their company's stock, providing transparency to investors.
Stakeholder Impact
- The transactions have a minimal impact on shareholders as they represent a small portion of the total outstanding shares.
Key Dates
| Date | Description |
|---|---|
| 03/01/2024 | Date of stock transactions: vesting of restricted stock units and disposal of shares for tax obligations. |
| 03/05/2024 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.